Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-02

Rhythm Pharmaceuticals, Inc. (RYTM)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$17,544,525
David Meeker total, FY2025
85th
CEO pay percentile vs peers
36:1
CEO-to-median pay ratio
81.41%
Say-on-pay support, latest vote
Companies that benchmark against RYTM
19 companies name RYTM as a compensation peer

Each company listed discloses RYTM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RYTM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
David Meeker$807,692$0$8,274,785$7,688,560$759,488$0$14,000$17,544,525
Chairman of the Board, President and Chief Executive Officer
Hunter Smith540,47702,933,2772,402,675338,000014,0006,228,429
Chief Financial Officer and Treasurer
Yann Mazabraud557,23102,839,7392,306,568344,659070,2586,118,455
Executive Vice President, Head of International
Jennifer Lee531,63502,649,8272,114,354293,000014,0005,602,816
Executive Vice President, Head of North America
Alastair Garfield505,38502,082,9271,537,712287,000014,0004,427,024
Chief Scientific Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
David Meeker$17,544,525$14,663,742$7,230,457+2,880,783
Hunter Smith6,228,4295,050,4102,308,007+1,178,019
Yann Mazabraud6,118,4555,621,6231,742,009+496,832
Jennifer Lee5,602,8164,318,2122,106,210+1,284,604
Alastair Garfield4,427,024

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dividend-equivalent accruals2026-05-154,4421 insider, 3 accrual rows
Christopher Paul GermanCorporate Controller & CAO2026-05-15A1,6875795,636CommonForm 4 ↗
Christopher Paul GermanCorporate Controller & CAO2026-05-15A1,3494966,411CommonForm 4 ↗
Christopher Paul GermanCorporate Controller & CAO2026-05-15A1,4061825,266CommonForm 4 ↗
Christopher Paul GermanCorporate Controller & CAO2026-05-15D4,64392428,131CommonForm 4 ↗
Hunter SmithChief Financial Officer2026-05-18D3,00000Derivative, Class A CommonForm 4 ↗
Hunter SmithChief Financial Officer2026-05-18A3,0001853,610CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-22D37,00000Derivative, Class A CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-22A37,000281,045,990CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-22D37,0001003,711,896CommonForm 4 ↗
David W. J. McGirrDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Stuart A. ArbuckleDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Jennifer GoodDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Christophe R. JeanDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
Jennifer GoodDirector2026-06-23A4,712CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-23A4,712CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Stuart A. ArbuckleDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Stuart A. ArbuckleDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
Jennifer GoodDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Jennifer GoodDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
David W. J. McGirrDirector2026-06-23A4,712CommonForm 4 ↗
David W. J. McGirrDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
David W. J. McGirrDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Stuart A. ArbuckleDirector2026-06-23A4,712CommonForm 4 ↗
Christophe R. JeanDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Christophe R. JeanDirector2026-06-23A4,712CommonForm 4 ↗
Christophe R. JeanDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Alastair GarfieldChief Scientific Officer2026-07-01A4,445CommonForm 4 ↗
Alastair GarfieldChief Scientific Officer2026-07-01D4,44500Derivative, Class A CommonForm 4 ↗
Alastair GarfieldChief Scientific Officer2026-07-01D2,150110237,382CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 35 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Christopher Paul GermanCorporate Controller & CAO2026-05-15D1,349$0$0Derivative, Class A CommonForm 4 ↗
Christopher Paul GermanCorporate Controller & CAO2026-05-15A1,6875795,636CommonForm 4 ↗
Christopher Paul GermanCorporate Controller & CAO2026-05-15A1,3494966,411CommonForm 4 ↗
Christopher Paul GermanCorporate Controller & CAO2026-05-15A1,4061825,266CommonForm 4 ↗
Christopher Paul GermanCorporate Controller & CAO2026-05-15D4,64392428,131CommonForm 4 ↗
Christopher Paul GermanCorporate Controller & CAO2026-05-15D1,40600Derivative, Class A CommonForm 4 ↗
Christopher Paul GermanCorporate Controller & CAO2026-05-15D1,68700Derivative, Class A CommonForm 4 ↗
Hunter SmithChief Financial Officer2026-05-18D3,00000Derivative, Class A CommonForm 4 ↗
Hunter SmithChief Financial Officer2026-05-18A3,0001853,610CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-22D37,00000Derivative, Class A CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-22A37,000281,045,990CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-22D37,0001003,711,896CommonForm 4 ↗
David W. J. McGirrDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Stuart A. ArbuckleDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Jennifer GoodDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Christophe R. JeanDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
Jennifer GoodDirector2026-06-23A4,712CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-23A4,712CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Stuart A. ArbuckleDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Stuart A. ArbuckleDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
Jennifer GoodDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Jennifer GoodDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
David W. J. McGirrDirector2026-06-23A4,712CommonForm 4 ↗
David W. J. McGirrDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
Lynn A. TetraultDirector2026-06-23A2,32400Derivative, Class A CommonForm 4 ↗
David W. J. McGirrDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Stuart A. ArbuckleDirector2026-06-23A4,712CommonForm 4 ↗
Christophe R. JeanDirector2026-06-23D4,71200Derivative, Class A CommonForm 4 ↗
Christophe R. JeanDirector2026-06-23A4,712CommonForm 4 ↗
Christophe R. JeanDirector2026-06-23A3,69100Derivative, Class A CommonForm 4 ↗
Alastair GarfieldChief Scientific Officer2026-07-01A4,445CommonForm 4 ↗
Alastair GarfieldChief Scientific Officer2026-07-01D4,44500Derivative, Class A CommonForm 4 ↗
Alastair GarfieldChief Scientific Officer2026-07-01D2,150110237,382CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Alastair GarfieldOPTION2025-02-1440,000$1,537,712
Yann MazabraudRSU2025-02-145,332572,139
Hunter SmithRSU2025-02-145,332572,139
David MeekerRSU2025-02-146,665715,173
Jennifer LeeRSU2025-02-1436,6502,077,689
Jennifer LeeRSU2025-02-145,332572,139
David MeekerRSU2025-02-14133,3507,559,612
Hunter SmithRSU2025-02-1441,6502,361,139
Yann MazabraudRSU2025-02-1440,0002,267,600
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Alastair Garfield$0$0$1,537,7120.0%
Yann Mazabraud2,839,739000.0%
Hunter Smith2,933,278000.0%
David Meeker8,274,785000.0%
Jennifer Lee2,649,828000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
David MeekerRSU28,250$3,023,880
Hunter SmithOption56,25030.66
David MeekerOption220,00030.66
Yann MazabraudOption25,00022.28
David MeekerRSU133,35014,273,784
David MeekerRSU63,7506,823,800
Yann MazabraudRSU34,6643,710,435
Hunter SmithRSU34,6643,710,435
Yann MazabraudRSU7,500802,800
Jennifer LeeRSU34,6643,710,435
David MeekerRSU43,3304,638,043
David MeekerOption71,75027.35
Hunter SmithOption61,00025.79
Hunter SmithOption45,22549.23
Alastair GarfieldRSU26,6502,852,616
Hunter SmithRSU4,062434,796
Yann MazabraudRSU16,5001,766,160
Alastair GarfieldRSU34,6643,710,435
Jennifer LeeRSU16,5001,766,160
Yann MazabraudOption5,1566.8
Hunter SmithOption82,00017.87
David MeekerOption145,68849.23
David MeekerOption10,00034.89
Yann MazabraudRSU40,0004,281,600
Jennifer LeeOption5,1566.8
Jennifer LeeRSU3,437367,896
Jennifer LeeRSU36,6503,923,016
Jennifer LeeOption37,10830.66
Jennifer LeeRSU9,024965,929
Hunter SmithOption50,78156.69
Hunter SmithOption16,75027.35
David MeekerOption15,00022.93
Jennifer LeeOption14,65627.35
Hunter SmithOption6,0946.8
David MeekerOption900,00022.53
Hunter SmithOption70,00029.78
David MeekerOption31,8756.8
David MeekerOption162,50056.69
Yann MazabraudOption48,75030.66
Hunter SmithOption25,00022.53
David MeekerOption65,4306.05
Hunter SmithRSU41,6504,458,216
Jennifer LeeOption71,28324.29
Hunter SmithRSU19,8002,119,392
Alastair GarfieldRSU13,3331,427,164
Yann MazabraudOption37,68749.23
Yann MazabraudOption48,75056.69
Hunter SmithRSU9,8501,054,344
Alastair GarfieldOption36,66743.76
Jennifer LeeOption37,68849.23
Jennifer LeeOption44,68856.69
Alastair GarfieldOption32,50056.69
David MeekerOption18,50021.37
05

Incentive-plan design — the Compensation Discussion & Analysis

The key objective of our executive compensation program is to attract, motivate, and reward leaders who create an inclusive and collaborative environment and have the skills and experience necessary to successfully execute on our strategic plan to maximize stockholder value.

CEO STI target (% of salary)75%
CEO LTI target (% of salary)
Independent consultantPay Governance LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-2450,368,65911,467,15736,68281.41%Passed
20252025-06-2540,890,84618,057,76310,08069.36%Passed
20242024-09-1850,612,2891,487,31716,55997.11%Passed
20232023-06-2138,842,2011,938,0945,879,08095.25%Passed
20222022-06-0829,672,1767,066,2191,133,97580.77%Passed
20212021-06-0933,591,2503,433,07592,41590.73%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-2481.41%a
20252025-06-2569.36%b
20242024-09-1897.11%c

a. Approved under the standard stated in the filing — “An abstention is treated as present and entitled to vote and, therefore, has the effect of a vote "against" the proposal.”.

b. Approved under the standard stated in the filing — “An abstention is treated as present and entitled to vote and, therefore, has the effect of a vote "against" the proposal.”.

c. Approved under the standard stated in the filing — “An abstention is treated as present and entitled to vote and, therefore, has the effect of a vote "against" the proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)36 : 1
CEO total compensation$17,544,525
Median employee compensation$484,876
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Edward T. MathersIndependent · Governance & Nominating Committee · Departed during FY$95,000$299,966$300,015$0$0$694,981
David W. J. McGirrIndependent · Audit Committee (Chair) · Governance & Nominating Committee75,000299,966300,01500674,981
Lynn A. TetraultIndependent · Lead Independent Director · Compensation & Management Development Committee (Chair) · Not standing for re-election70,000299,966300,01500669,981
Camille BedrosianIndependent · Compensation & Management Development Committee · Governance & Nominating Committee · Departed during FY65,000299,966300,01500664,981
Christophe R. JeanIndependent · Audit Committee · Governance & Nominating Committee · Not standing for re-election60,000299,966300,01500659,981
Jennifer GoodIndependent · Audit Committee · Not standing for re-election60,000299,966300,01500659,981
Stuart A. ArbuckleIndependent · Governance & Nominating Committee (Chair) · Compensation & Management Development Committee · Not standing for re-election60,000299,966300,01500659,981
Kimberly J. PopovitsIndependent · Compensation & Management Development Committee · Not standing for re-election · Newly elected000000
David P. MeekerEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$599,981
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 20,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$485,000
Equity awards (grant-date value)$2,099,762
All other compensation$0
Total cost of the board$2,584,762

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Rhythm Pharmaceuticals, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Rhythm Pharmaceuticals, Inc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Ocular Therapeutix2025Pravin Dugel$819,200$18,608,000$15,567,000$0$35,946,958
2TG Therapeutics2025Michael Weiss875,00023,550,00001,146,25025,571,250
3PTC Therapeutics, Inc.2025Matthew Klein958,50016,593,8004,399,7601,294,00023,266,326
4Rhythm Pharmaceuticals, Inc.2025David Meeker807,6928,274,7857,688,560759,48817,544,525
5SpringWorks Therapeutics2024Saqib Islam760,0007,899,7606,689,100798,00016,153,317
6BridgeBio Pharma, Inc.2025Neil Kumar1,044,00010,606,2751,874,992014,944,585
7Insmed Incorporated2025William Lewis854,5502,999,9409,000,0331,495,46314,467,393
8Blueprint Medicines Corporation2024Kathryn Haviland821,3637,472,4804,315,144854,21713,477,004
9BioCryst Pharmaceuticals2025Jon Stonehouse728,466011,132,4581,052,63312,951,082
10Ultragenyx Pharmaceuticals2025Emil Kakkis861,1008,364,9381,847,356299,66311,405,535
11Vericel Corporation2025Dominick Colangelo860,0003,964,6305,456,287860,00011,156,368
12Apellis Pharmaceuticals2024Cedric Francois793,1934,779,8324,787,768010,957,451
13Krystal Biotech, Inc.2025Krish Krishnan846,1674,104,8254,675,093010,442,485
14Mirum Pharmaceuticals, Inc.2025Christopher Peetz755,0003,683,9044,931,3201,057,00010,441,224
15Intra-Cellular Therapies2023Sharon Mates891,6537,749,9840010,086,413
16Amicus Therapeutics2024Bradley Campbell767,3084,990,3652,105,62708,526,943
17Travere Therapeutics2025Eric Dube854,2503,314,5203,309,384964,1258,457,151
18Ardelyx2025Michael Raab797,0002,953,7243,413,948627,6387,796,171
19Catalyst Pharmaceuticals, Inc.2024Richard Daly750,0001,267,6015,070,83007,774,160
20Agios Pharmaceuticals2025Brian Goff846,8641,291,6802,627,252592,8045,370,389
21Ironwood Pharmaceuticals2025Thomas McCourt867,568411,6960650,6761,948,390

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Rhythm Pharmaceuticals, Inc.120%Options 50 · RSU 50NoPay Governance LLC
Agios Pharmaceuticals100%Options 40 · PSU 40 · RSU 20NoAon
Amicus Therapeutics108%Options 33 · RSU 33 · PSU 33Yes — TSR GoalPay Governance
Apellis Pharmaceuticals90.74%not disclosedYes — Total Shareholder Return (TSR) relative to NASDAQ Biotechnology IndexPay Governance
Ardelyx105%Options 50 · RSU 50not disclosedPearl Meyer
BioCryst Pharmaceuticals170%not disclosednot disclosedAon Human Capital Solutions (division of Aon plc)
Blueprint Medicines Corporation130%RSU 37 · Options 32 · PSU 31Yes — Relative Total Stockholder Return (rTSR)Aon (Human Capital Solutions practice, formerly Radford)
BridgeBio Pharma, Inc.135%RSU 50 · PSU 35 · Options 15NoAon Talent Solutions
Catalyst Pharmaceuticals, Inc.105%not disclosednot disclosedMercer LLC (a business of Marsh McLennan)
Insmed Incorporated175%Options 75 · RSU 25NoWillis Towers Watson (WTW)
Intra-Cellular Therapies150%RSU 75 · PSU 25Yes — Total Stockholder Return (TSR) relative to Nasdaq Biotechnology IndexAon Consulting, Inc.
Ironwood Pharmaceuticals100%PSU 50 · RSU 50Yes — relative total stockholder return (rTSR)Alpine Rewards LLC
Krystal Biotech, Inc.100%not disclosednot disclosedCompensia, Inc.
Mirum Pharmaceuticals, Inc.200%not disclosedNoAlpine Rewards
Ocular Therapeutix145%not disclosedNoAon
PTC Therapeutics, Inc.167%Options 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFW Cook
SpringWorks Therapeutics140%not disclosedYes — Relative Total Shareholder Return (TSR)Aon plc (Human Capital Solutions practice)
TG Therapeutics131%RSU 100NoCompensia, Inc.
Travere Therapeutics150%not disclosedNoAon
Ultragenyx Pharmaceuticals44%PSU 60 · RSU 20 · Options 20Yes — Relative TSRAon's Human Capital Solutions Practice
Vericel Corporation100%Options 58 · RSU 42not disclosedFW Cook

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Rhythm Pharmaceuticals, Inc. in fiscal 2025?
David Meeker, serving as Chairman of the Board, President and Chief Executive Officer, was the highest-paid executive at Rhythm Pharmaceuticals, Inc. in fiscal 2025 with total compensation of $17,544,525.
How does Rhythm Pharmaceuticals, Inc.'s chief executive pay compare to its disclosed peer group?
The filing shows that the CEO's pay placed him in the 85th percentile of the disclosed peer group.
What is Rhythm Pharmaceuticals, Inc.'s CEO-to-median employee pay ratio?
The company reported a CEO-to-median employee pay ratio of 36:1 for fiscal 2025.
How did shareholders vote on Rhythm Pharmaceuticals, Inc.'s executive compensation?
Shareholders cast a vote supporting the executive compensation plan with 81.41% approval.
How much does Rhythm Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2025?
The total board compensation for fiscal 2025 was $2,584,762.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, David MeekerDEF 14A2026-04-290001628280-26-028375Section “2025 Summary Compensation Table”. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074
2Section 01, Hunter SmithDEF 14A2026-04-290001628280-26-028375Section “2025 Summary Compensation Table”. As printed: 6,228,429. Filing ↗machine: r5 · c42 · span 524032–524041
3Section 01, Yann MazabraudDEF 14A2026-04-290001628280-26-028375Section “2025 Summary Compensation Table”. As printed: 6,118,455. Filing ↗machine: span 546284–546293
4Section 01, Jennifer LeeDEF 14A2026-04-290001628280-26-028375Section “2025 Summary Compensation Table”. As printed: 5,602,816. Filing ↗machine: r8 · c42 · span 534970–534979
5Section 01, Alastair GarfieldDEF 14A2026-04-290001628280-26-028375Section “2025 Summary Compensation Table”. As printed: 4,427,024. Filing ↗machine: r14 · c42 · span 557311–557320
6Section 03, Alastair Garfield OPTIONDEF 14A2026-04-290001628280-26-028375Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r20 · c26 · span 645658–645667
7Section 03, Yann Mazabraud RSUDEF 14A2026-04-290001628280-26-028375Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r18 · c26 · span 637564–637571
8Section 03, Hunter Smith RSUDEF 14A2026-04-290001628280-26-028375Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r10 · c26 · span 604642–604649
9Section 03, David Meeker RSUDEF 14A2026-04-290001628280-26-028375Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r6 · c26 · span 588179–588186
10Section 03, Jennifer Lee RSUDEF 14A2026-04-290001628280-26-028375Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r13 · c26 · span 617058–617067
11Section 03, Jennifer Lee RSUDEF 14A2026-04-290001628280-26-028375Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r14 · c26 · span 621102–621109
12Section 03, David Meeker RSUDEF 14A2026-04-290001628280-26-028375Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r5 · c26 · span 584135–584144
13Section 03, Hunter Smith RSUDEF 14A2026-04-290001628280-26-028375Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r9 · c26 · span 600598–600607
14Section 03, Yann Mazabraud RSUDEF 14A2026-04-290001628280-26-028375Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r17 · c26 · span 633520–633529
15Section 07, pay ratioDEF 14A2026-04-290001628280-26-028375Section “CEO Pay Ratio”. As printed: 36 : 1. Filing ↗machine: span 891733–891735
16Section 08, Edward T. MathersDEF 14A2026-04-290001628280-26-028375Section “Director Compensation”. As printed: 694,981. Filing ↗machine: t10 · r6 · c15 · span 251471–251478
17Section 08, David W. J. McGirrDEF 14A2026-04-290001628280-26-028375Section “Director Compensation”. As printed: 674,981. Filing ↗machine: t10 · r7 · c15 · span 254172–254179
18Section 08, Lynn A. TetraultDEF 14A2026-04-290001628280-26-028375Section “Director Compensation”. As printed: 669,981. Filing ↗machine: t10 · r8 · c15 · span 256871–256878
19Section 08, Camille BedrosianDEF 14A2026-04-290001628280-26-028375Section “Director Compensation”. As printed: 664,981. Filing ↗machine: t10 · r3 · c15 · span 243374–243381
20Section 08, Christophe R. JeanDEF 14A2026-04-290001628280-26-028375Section “Director Compensation”. As printed: 659,981. Filing ↗machine: t10 · r5 · c15 · span 248771–248778
21Section 08, Jennifer GoodDEF 14A2026-04-290001628280-26-028375Section “Director Compensation”. As printed: 659,981. Filing ↗machine: t10 · r4 · c15 · span 246070–246077
22Section 08, Stuart A. ArbuckleDEF 14A2026-04-290001628280-26-028375Section “Director Compensation”. As printed: 659,981. Filing ↗machine: t10 · r2 · c15 · span 240632–240639
23Section 08, Kimberly J. PopovitsDEF 14A2026-04-290001628280-26-028375Section “Director Compensation”. As printed: 0. Filing ↗
24Section 08, David P. MeekerDEF 14A2026-04-290001628280-26-028375Section “Director Compensation”. As printed: 0. Filing ↗
25Section 02, Christopher Paul German 2026-05-15Form 42026-05-190001104659-26-063830Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Christopher Paul German 2026-05-15Form 42026-05-190001104659-26-063830Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Christopher Paul German 2026-05-15Form 42026-05-190001104659-26-063830Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Christopher Paul German 2026-05-15Form 42026-05-190001104659-26-063830Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Christopher Paul German 2026-05-15Form 42026-05-190001104659-26-063830Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Christopher Paul German 2026-05-15Form 42026-05-190001104659-26-063830Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Christopher Paul German 2026-05-15Form 42026-05-190001104659-26-063830Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Hunter Smith 2026-05-18Form 42026-05-200001104659-26-064516Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Hunter Smith 2026-05-18Form 42026-05-200001104659-26-064516Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Lynn A. Tetrault 2026-06-22Form 42026-06-240001104659-26-077305Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Lynn A. Tetrault 2026-06-22Form 42026-06-240001104659-26-077305Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Lynn A. Tetrault 2026-06-22Form 42026-06-240001104659-26-077305Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, David W. J. McGirr 2026-06-23Form 42026-06-250001104659-26-077866Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Lynn A. Tetrault 2026-06-23Form 42026-06-250001104659-26-077864Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Stuart A. Arbuckle 2026-06-23Form 42026-06-250001104659-26-077863Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Jennifer Good 2026-06-23Form 42026-06-250001104659-26-077862Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Christophe R. Jean 2026-06-23Form 42026-06-250001104659-26-077867Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Jennifer Good 2026-06-23Form 42026-06-250001104659-26-077862Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Lynn A. Tetrault 2026-06-23Form 42026-06-250001104659-26-077864Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Lynn A. Tetrault 2026-06-23Form 42026-06-250001104659-26-077864Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Stuart A. Arbuckle 2026-06-23Form 42026-06-250001104659-26-077863Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Stuart A. Arbuckle 2026-06-23Form 42026-06-250001104659-26-077863Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Jennifer Good 2026-06-23Form 42026-06-250001104659-26-077862Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Jennifer Good 2026-06-23Form 42026-06-250001104659-26-077862Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, David W. J. McGirr 2026-06-23Form 42026-06-250001104659-26-077866Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, David W. J. McGirr 2026-06-23Form 42026-06-250001104659-26-077866Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Lynn A. Tetrault 2026-06-23Form 42026-06-250001104659-26-077864Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, David W. J. McGirr 2026-06-23Form 42026-06-250001104659-26-077866Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Stuart A. Arbuckle 2026-06-23Form 42026-06-250001104659-26-077863Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Christophe R. Jean 2026-06-23Form 42026-06-250001104659-26-077867Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Christophe R. Jean 2026-06-23Form 42026-06-250001104659-26-077867Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Christophe R. Jean 2026-06-23Form 42026-06-250001104659-26-077867Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Alastair Garfield 2026-07-01Form 42026-07-020001104659-26-080397Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Alastair Garfield 2026-07-01Form 42026-07-020001104659-26-080397Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Alastair Garfield 2026-07-01Form 42026-07-020001104659-26-080397Insider equity transaction reported since the proxy statement. Filing ↗
60Section 06, 2026 voteForm 8-K2026-06-250001628280-26-045569Item 5.07 · say-on-pay result. As reported: 81.41% (votes for as printed: 50,368,659). Filing ↗
61Section 06, 2025 voteForm 8-K2025-06-260001558370-25-008924Item 5.07 · say-on-pay result. As reported: 69.36% (votes for as printed: 40,890,846). Filing ↗
62Section 06, 2024 voteForm 8-K2024-09-190001104659-24-101393Item 5.07 · say-on-pay result. As reported: 97.11% (votes for as printed: 50,612,289). Filing ↗
63Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
64Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
65Section 09b board cost (computed)ComputedcomputedCash 485,000 + equity 2,099,762 + all other 0 = 2,584,762, summed across the director compensation table rows.machine: formula: Σ = 2,584,762
66Ocular Therapeutix, Section 10b CEO totalDEF 14A2026-04-300001104659-26-053176CEO total compensation as printed in Ocular Therapeutix's own proxy. As printed: 35,946,958. Filing ↗machine: t128 · r3 · c15 · span 574379–574389
67TG Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001437749-26-014233CEO total compensation as printed in TG Therapeutics's own proxy. As printed: 25,571,250. Filing ↗machine: r4 · c24 · span 404551–404561
68PTC Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗machine: t148 · r6 · c16 · span 769400–769410
69Rhythm Pharmaceuticals, Inc. (subject), Section 10b CEO totalDEF 14A2026-04-290001628280-26-028375CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074
70SpringWorks Therapeutics, Section 10b CEO totalDEF 14A2025-04-040001104659-25-032187CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. Filing ↗machine: t23 · r1 · c44 · span 623184–623194
71BridgeBio Pharma, Inc., Section 10b CEO totalDEF 14A2026-04-240001140361-26-016723CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531
72Insmed Incorporated, Section 10b CEO totalDEF 14A2026-04-010001104506-26-000022CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563
73Blueprint Medicines Corporation, Section 10b CEO totalDEF 14A2025-04-240001558370-25-005415CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. Filing ↗machine: t150 · r5 · c14 · span 1101152–1101162
74BioCryst Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001628280-26-026822CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266
75Ultragenyx Pharmaceuticals, Section 10b CEO totalDEF 14A2026-03-270001308179-26-000174CEO total compensation as printed in Ultragenyx Pharmaceuticals's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007
76Vericel Corporation, Section 10b CEO totalDEF 14A2026-03-190001308179-26-000094CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754
77Apellis Pharmaceuticals, Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
78Krystal Biotech, Inc., Section 10b CEO totalDEF 14A2026-04-030001711279-26-000036CEO total compensation as printed in Krystal Biotech, Inc.'s own proxy. As printed: 10,442,485. Filing ↗machine: span 547434–547444
79Mirum Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001759425-26-000027CEO total compensation as printed in Mirum Pharmaceuticals, Inc.'s own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210
80Intra-Cellular Therapies, Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
81Amicus Therapeutics, Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137
82Travere Therapeutics, Section 10b CEO totalDEF 14A2026-04-060001438533-26-000027CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523
83Ardelyx, Section 10b CEO totalDEF 14A2026-04-290001140361-26-017800CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121
84Catalyst Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2025-04-110001193125-25-079097CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. Filing ↗machine: r3 · c31 · span 285833–285842
85Agios Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177086CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194
86Ironwood Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-280001104659-26-050325CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. Filing ↗machine: t29 · r1 · c48 · span 584182–584191
87Section 10a, Agios Pharmaceuticals reciprocityDEF 14A0001193125-26-177086Agios Pharmaceuticals names Rhythm Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
88Section 10a, Catalyst Pharmaceuticals, Inc. reciprocityDEF 14A0001193125-25-079097Catalyst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
89Section 10a, Intra-Cellular Therapies reciprocityDEF 14A0001628280-24-018986Intra-Cellular Therapies's most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
90Section 10a, Krystal Biotech, Inc. reciprocityDEF 14A0001711279-26-000036Krystal Biotech, Inc.'s most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
91Section 10a, Amicus Therapeutics reciprocityDEF 14A0001140361-25-015479Amicus Therapeutics's most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
92Section 10a, Apellis Pharmaceuticals reciprocityDEF 14A0000950170-25-056966Apellis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
93Section 10a, Ardelyx reciprocityDEF 14A0001140361-26-017800Ardelyx names Rhythm Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
94Section 10a, Blueprint Medicines Corporation reciprocityDEF 14A0001558370-25-005415Blueprint Medicines Corporation's most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
95Section 10a, PTC Therapeutics, Inc. reciprocityDEF 14A0001104659-26-045528PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
96Section 10a, SpringWorks Therapeutics reciprocityDEF 14A0001104659-25-032187SpringWorks Therapeutics's most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
97Section 10a, Ultragenyx Pharmaceuticals reciprocityDEF 14A0001308179-26-000174Ultragenyx Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
98Section 10a, Vericel Corporation reciprocityDEF 14A0001308179-26-000094Vericel Corporation names Rhythm Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
99Section 10a, Insmed Incorporated reciprocityDEF 14A0001104506-26-000022Insmed Incorporated's most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
100Section 10a, Mirum Pharmaceuticals, Inc. reciprocityDEF 14A0001759425-26-000027Mirum Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
101Section 10a, BioCryst Pharmaceuticals reciprocityDEF 14A0001628280-26-026822BioCryst Pharmaceuticals names Rhythm Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
102Section 10a, Ocular Therapeutix reciprocityDEF 14A0001104659-26-053176Ocular Therapeutix's most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
103Section 10a, TG Therapeutics reciprocityDEF 14A0001437749-26-014233TG Therapeutics's most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
104Section 10a, BridgeBio Pharma, Inc. reciprocityDEF 14A0001140361-26-016723BridgeBio Pharma, Inc.'s most recent proxy was read; its disclosed peer group does not include Rhythm Pharmaceuticals, Inc.. Filing ↗
105Section 10a, Travere Therapeutics reciprocityDEF 14A0001438533-26-000027Travere Therapeutics names Rhythm Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗